Animal health product developer Bactana is advancing Cornell University research into probiotics that could lead to improved vitality for livestock including cattle, swine and poultry.
Bactana, a US-based animal health product developer that has licensed Cornell University research, has closed a $1.3m equity round featuring Cornell and Connecticut Innovations, the venture capital vehicle for the State of Connecticut.
VC fund Sustainable Income Capital Management also took part in the round, as did unnamed additional funds and private investors. The deal includes conversions of existing debt and interest instruments.
Founded in 2016, Bactana has devised a microbiome discovery platform that identifies targets in the gut microbiome of farming and companion animals in order to develop probiotic animal health products.
The probiotics, which contain naturally-occurring bacteria branded Pioneer Gut Colonizers, will offer an alternative to antibiotics, which become increasingly ineffective over time. The gut microbiome has been linked to a range of health considerations.
The approach was discovered by a research team led by Bactana’s chief scientific officer Rodrigo Bicalho, professor of dairy…
